Skip to main content
. Author manuscript; available in PMC: 2012 Sep 13.
Published in final edited form as: Leuk Lymphoma. 2011 Jun 24;52(8):1463–1473. doi: 10.3109/10428194.2011.574754

Figure 1. Outcomes for total population.

Figure 1

All curves are for the 37-patient population with a median follow-up of 64 months for survivors. Panel A shows the Kaplan-Meier estimate of survival probability. Panel B shows progression-free survival, defined as time from stem cell infusion to recurrence, progression, or death from any cause, whichever occurred first. Panel C shows cumulative incidence of relapse/progression, defined as time from stem cell infusion to recurrence or progression. Panel D shows non-relapse mortality, measured as time from stem cell infusion to death from any cause other than disease relapse or disease progression. In panels C and D, relapse/progression and non-relapse mortality were treated as competing risks.